Iterum Therapeutics (Iterum Therapeutics) ROCE % : -262.02% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Iterum Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Iterum Therapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -262.02%.

Iterum Therapeutics ROCE % Historical Data

The historical data trend for Iterum Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iterum Therapeutics ROCE % Chart

Iterum Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-273.66

-244.91

-61.28

-103.05

Iterum Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-33.29	-69.33	-103.69	-43.02	-262.02

Iterum Therapeutics ROCE % Calculation

Iterum Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-36.33	/	( ( (66.833 - 9.064)	+	(26.259 - 13.518) )	/ 2 )
	=	-36.33	/	( (57.769	+	12.741)	/ 2 )
	=	-36.33	/	35.255
	=	-103.05 %

Iterum Therapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-47.26	/	( ( (39.728 - 16.396)	+	(26.259 - 13.518) )	/ 2 )
	=	-47.26	/	( ( 23.332	+	12.741 )	/ 2 )
	=	-47.26	/	18.0365
	=	-262.02 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Iterum Therapeutics (NAS:ITRM) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Iterum Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Iterum Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Iterum Therapeutics (Iterum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iterum Therapeutics PLC (NAS:ITRM) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Fitzwilliam Court, 1st Floor, Leeson Close, Dublin, IRL, 2

Website

https://www.iterumtx.com

Iterum Therapeutics PLC is a clinical-stage pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents. The company operates as a single business segment, which is the development and commercialization of innovative treatments for drug-resistant bacterial infections.

Executives

Michael W. Dunne	officer: Chief Scientific Officer	DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Fishman Corey N.	director, officer: President & CEO	DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Sailaja Puttagunta	officer: Chief Medical Officer	C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Brenton Karl Ahrens	director	2765 SAND HILL ROAD, MENLO PARK CA 94025
Judith M. Matthews	officer: Chief Financial Officer	200 WEST MONROE ST., SUITE 1575, CHICAGO IL 60606
Beth Hecht	director	C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
Alexander J Denner	10 percent owner	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Hawkeye Fund Lp	10 percent owner	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Catapult Fund Llc	10 percent owner	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Master Fund Ii Lp	10 percent owner	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Offshore Master Fund Lp	10 percent owner	C/O SARISSA CAPITAL MANAGEMENT, 660 STEAMBOAT ROAD 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Management Lp	10 percent owner	660 STEAMBOAT ROAD, GREENWICH CT 06830
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116